MedKoo product information:

 Vinorelbine tartrate

Vinorelbine tartrate is the ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

DRUG DESCRIPTION

NAVELBINE (vinorelbine tartrate) Injection is for intravenous administration. Each vial contains vinorelbine tartrate equivalent to 10 mg (1-mL vial) or 50 mg (5-mL vial) vinorelbine in Water for Injection. No preservatives or other additives are present. The aqueous solution is sterile and nonpyrogenic. Vinorelbine tartrate is a semi-synthetic vinca alkaloid with antitumor activity. The chemical name is 3',4'-didehydro-4'-deoxy-C'-norvincaleukoblastine [R-(R*,R*)-2, 3-dihydroxybutanedioate (1:2)(salt)]. vinorelbine tartrate is a white to yellow or light brown amorphous powder with the molecular formula C45H54N4O8•2C4H6O6 and molecular weight of 1079.12. The aqueous solubility is > 1,000 mg/mL in distilled water. The pH of NAVELBINE Injection is approximately 3.5.

Oral formulation

An oral formulation has been marketed and registered in most European coutries for the same settings. It has similar efficacy as the intravenous formulation, avoids venous toxicities of an infusion and is easier to take. from: http://en.wikipedia.org/wiki/Vinorelbine.

CLINICAL PHARMACOLOGY

Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. Unlike other vinca alkaloids, the catharanthine unit is the site of structural modification for vinorelbine. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca++-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. In intact tectal plates from mouse embryos, vinorelbine, vincristine and vinblastine inhibited mitotic microtubule formation at the same concentration (2 µM), inducing a blockade of cells at metaphase. Vincristine produced depolymerization of axonal microtubules at 5 µM, but vinblastine and vinorelbine did not have this effect until concentrations of 30 µM and 40 µM, respectively. These data suggest relative selectivity of vinorelbine for mitotic microtubules.

History

Vinorelbine was invented by the pharmacist Pierre Potier and his team from the CNRS in France in the 1980s and was licensed to the oncology department of the Pierre Fabre Group. The drug was approved in France in 1989 under the brand name Navelbine for the treatment of non-small cell lung cancer. It gained approval to treat metastatic breast cancer in 1991. Vinorelbine received approval by the United States Food and Drug Administration (FDA) in December 1994 sponsored by Burroughs Wellcome Company. Pierre Fabre Group now markets Navelbine in the U.S. where the drug went generic in February 2003. In most European countries, it is approved to treat non-small cell lung cancer and breast cancer. from: http://en.wikipedia.org/wiki/Vinorelbine.

 1: Kountourakis P, Missitzis I, Doufexis D, Zobolas V, Pissakas G, Arnogiannaki N, Maliou S, Sotiropoulou A, Ardavanis A. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer. J Cancer Res Clin Oncol. 2010 Apr 13. [Epub ahead of print] PubMed PMID: 20387073.

2: Emmanouilides C, Yermetaki T, Serpanou A, Sapountzi E, Mantziari P, Titopoulos I, Filippou D. Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer. Hematol Oncol Stem Cell Ther. 2010;3(1):34-8. PubMed PMID: 20231811.

3: Lünenbürger H, Lanvers-Kaminsky C, Lechtape B, Frühwald MC. Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs. 2010 Jun;21(5):514-22. PubMed PMID: 20147838.

4: Watanabe K, Tanimura S, Uchiyama A, Sakamoto T, Kawabata T, Ozaki K, Kohno M. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models. Clin Cancer Res. 2010 Feb 15;16(4):1170-8. Epub 2010 Feb 9. PubMed PMID: 20145173.

5: Barnett CM. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer. Pharmacotherapy. 2009 Dec;29(12):1482-90. PubMed PMID: 19947807.

6: Yamada T, Egashira N, Imuta M, Yano T, Yamauchi Y, Watanabe H, Oishi R. Role of oxidative stress in vinorelbine-induced vascular endothelial cell injury. Free Radic Biol Med. 2010 Jan 1;48(1):120-7. Epub 2009 Oct 27. PubMed PMID: 19837156.

7: Kohno E, Murase S, Matsuyama K, Okamura N. Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits. Int J Med Sci. 2009 Aug 6;6(5):218-23. PubMed PMID: 19680474; PubMed Central PMCID: PMC2726577.

8: Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Imamura F, Minamikawa K, Takano T, Kobayashi H. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer. 2010 Jun;68(3):472-7. Epub 2009 Aug 5. PubMed PMID: 19660825.

9: Owonikoko TK, Sun SY, Ramalingam SS. The role of cetuximab in the management of non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul;10(4):230-8. Review. PubMed PMID: 19632939.

10: Bourgarel-Rey V, Savry A, Hua G, Carré M, Bressin C, Chacon C, Imbert J, Braguer D, Barra Y. Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem Pharmacol. 2009 Nov 1;78(9):1148-56. Epub 2009 Jun 23. PubMed PMID: 19555669.

11: Rabbani-Chadegani A, Chamani E, Hajihassan Z. The effect of vinca alkaloid anticancer drug, vinorelbine, on chromatin and histone proteins in solution. Eur J Pharmacol. 2009 Jun 24;613(1-3):34-8. Epub 2009 Apr 24. PubMed PMID: 19394329.

12: Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, Mora A, Porro G. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer. In Vivo. 2009 Jan-Feb;23(1):171-5. PubMed PMID: 19368145.

13: Bessho Y, Oguri T, Ozasa H, Uemura T, Sakamoto H, Miyazaki M, Maeno K, Sato S, Ueda R. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep. 2009 Jan;21(1):263-8. PubMed PMID: 19082471.

14: Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer. 2008 Dec 2;99(11):1808-15. PubMed PMID: 19034280; PubMed Central PMCID: PMC2600681.

15: Ferguson PJ, Brisson AR, Koropatnick J, Vincent MD. Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett. 2009 Feb 18;274(2):279-89. Epub 2008 Nov 4. PubMed PMID: 18986763.

16: Takigawa N, Tanimoto M. [Vinca alkaloid and MDR1]. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9. Japanese. PubMed PMID: 18633246.

17: Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Pang VF, Wang SJ, Whang-Peng J, Ting G. Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol. 2008 Jul;35(5):623-34. PubMed PMID: 18589307.

18: Wan F, You J, Sun Y, Zhang XG, Cui FD, Du YZ, Yuan H, Hu FQ. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm. 2008 Jul 9;359(1-2):104-10. Epub 2008 Mar 28. PubMed PMID: 18450394.

19: Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol. 2008 Apr;35(2 Suppl 2):S31-8; quiz S40. Review. PubMed PMID: 18410797.

20: Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV. Dose enhancement effect of anticaner drugs associated with increased temperature in vitro. Exp Oncol. 2008 Mar;30(1):56-9. PubMed PMID: 18438342.

21: Simoens C, Lardon F, Pauwels B, De Pooter CM, Lambrechts HA, Pattyn GG, Breillout F, Vermorken JB. Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer. 2008 Feb 29;8:65. PubMed PMID: 18312675; PubMed Central PMCID: PMC2311317.

22: Quan H, Xu Y, Lou L. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. Int J Cancer. 2008 Apr 15;122(8):1730-7. PubMed PMID: 18074350.

23: Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, Elliott P, Borisy AA, Keith CT. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res. 2007 Dec 1;67(23):11359-67. PubMed PMID: 18056463.

24: Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol. 2008 Feb;19(2):212-22. Epub 2007 Nov 15. Review. PubMed PMID: 18006898.

25: Ishiura Y, Terasaki Y, Yamamoto H, Yokawa S, Fukushima W, Hirosawa H, Izumi R, Tanikawa F, Maruyama K, Ichihashi K, Miyazu M, Yoneda K, Kasahara K, Fujimura M. [Analysis of factors associated with quality of life for patients with non-small lung cancer receiving outpatient vinorelbine therapy as alternative inpatient therapy]. Gan To Kagaku Ryoho. 2007 Sep;34(9):1401-4. Japanese. PubMed PMID: 17876137.

26: Ardavanis A, Kountourakis P, Maliou S, Vassilakopoulou M, Basioukas S, Kyriakou F, Koumna S, Rigatos G. Gemcitabine and oral vinorelbine as salvage treatment in patients with advanced anthracycline- and taxane-pretreated breast cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2989-92. PubMed PMID: 17695483.

27: Selvaggi G, Scagliotti GV. Perspectives in adjuvant chemotherapy in NSCLC. Expert Rev Respir Med. 2007 Aug;1(1):99-110. PubMed PMID: 20477270.

28: Li C, Gemma A, Minegishi Y, Matsuda K, Seike Y, Noro R, Shionoya A, Kawakami A, Ogawa N, Kudoh S. In vitro simulation study of individualized chemotherapy in lung cancer. J Nippon Med Sch. 2007 Jun;74(3):217-22. PubMed PMID: 17625370.

29: Lang DS, Droemann D, Schultz H, Branscheid D, Martin C, Ressmeyer AR, Zabel P, Vollmer E, Goldmann T. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respir Res. 2007 Jun 14;8:43. PubMed PMID: 17567922; PubMed Central PMCID: PMC1913052.

30: Cardile V, Chillemi R, Lombardo L, Sciuto S, Spatafora C, Tringali C. Antiproliferative activity of methylated analogues of E- and Z-resveratrol. Z Naturforsch C. 2007 Mar-Apr;62(3-4):189-95. PubMed PMID: 17542483.

31: Abiko T, Kawamura M, Izumi Y, Oyama T, Saito Y, Kobayashi K. Prediction of anti-tumour effect of thermochemotherapy with in vitro thermochemosensitivity testing for non-small cell lung cancer. Int J Hyperthermia. 2007 May;23(3):267-75. PubMed PMID: 17523019.

32: Yoneda S. [Outpatient chemotherapy for lung cancer]. Gan To Kagaku Ryoho. 2007 Apr;34(4):533-7. Japanese. PubMed PMID: 17431337.

33: Aapro MS, Conte P, Esteban González E, Trillet-Lenoir V. Oral vinorelbine: role in the management of metastatic breast cancer. Drugs. 2007;67(5):657-67. Review. PubMed PMID: 17385939.

34: Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, Park MS, Chung KY, Lee HJ, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer. 2007 May 1;109(9):1829-35. PubMed PMID: 17366594.

35: Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, Kadota J. [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy]. Nihon Kokyuki Gakkai Zasshi. 2007 Feb;45(2):166-9. Japanese. PubMed PMID: 17352174.

36: Celikler S, Bilaloğlu R, Aydemir N. Genotoxic effects induced by fotemustine and vinorelbine in human lymphocytes. Z Naturforsch C. 2006 Nov-Dec;61(11-12):903-10. PubMed PMID: 17294704.

37: Wu S, Guo W, Teraishi F, Pang J, Kaluarachchi K, Zhang L, Davis J, Dong F, Yan B, Fang B. Anticancer activity of 5-benzylidene-2-phenylimino-1, 3-thiazolidin-4-one (BPT) analogs. Med Chem. 2006 Nov;2(6):597-605. PubMed PMID: 17105441.

38: Koukoulitsa C, Kyrikou I, Demetzos C, Mavromoustakos T. The role of the anticancer drug vinorelbine in lipid bilayers using differential scanning calorimetry and molecular modeling. Chem Phys Lipids. 2006 Oct;144(1):85-95. Epub 2006 Jul 29. PubMed PMID: 16962086.

39: Kobayashi M, Matsui K, Hirashima T, Nitta T, Sasada S, Tada T, Minakuchi K, Furukawa M, Ogata Y, Kawase I. Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. Int J Clin Oncol. 2006 Aug;11(4):314-9. PubMed PMID: 16937306.

40: Gemma A, Li C, Sugiyama Y, Matsuda K, Seike Y, Kosaihira S, Minegishi Y, Noro R, Nara M, Seike M, Yoshimura A, Shionoya A, Kawakami A, Ogawa N, Uesaka H, Kudoh S. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer. 2006 Jun 30;6:174. PubMed PMID: 16813650; PubMed Central PMCID: PMC1533844.

41: Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, Chrysochoou M, Sotiropoulou A, Arnogiannaki N, Ioannidis G, Pissakas G, Rigatos G. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist. 2006 Jun;11(6):563-73. PubMed PMID: 16794236.

42: Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Saijo N, Tamura T. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer. 2006 Aug;53(2):157-64. Epub 2006 Jun 15. PubMed PMID: 16781004.

43: Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006 Aug;32(6):676-81. Epub 2006 Apr 17. Review. PubMed PMID: 16616827.

44: Montenegro-Alvarez P, González-Alfonso M, Cantarino-Aragón MH, Gutiérrez-Ortega C, Guijarro-Escribano FJ. [Microsomal oxidative metabolism in the liver of rats treated with vinorelbine: evaluation through antipyrine elimination]. Gastroenterol Hepatol. 2006 Apr;29(4):224-30. Spanish. PubMed PMID: 16584692.

45: Fujiwara T, Kagawa S, Kishimoto H, Endo Y, Hioki M, Ikeda Y, Sakai R, Urata Y, Tanaka N, Fujiwara T. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer. 2006 Jul 15;119(2):432-40. PubMed PMID: 16477640.

46: Schmidt MS, Huang R, Classon RJ, Murry DJ. Determination of vincristine in infant plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectroscopy. J Pharm Biomed Anal. 2006 May 3;41(2):540-3. Epub 2006 Jan 18. PubMed PMID: 16414232.

47: Ando K, Ohmori T, Inoue F, Kadofuku T, Hosaka T, Ishida H, Shirai T, Okuda K, Hirose T, Horichi N, Nishio K, Saijo N, Adachi M, Kuroki T. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8872-9. PubMed PMID: 16361577.

48: Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005 Dec 15;65(24):11631-8. PubMed PMID: 16357174.

49: Ardavanis A, Tryfonopoulos D, Orphanos G, Ioannidis G, Karamouzis M, Rigatos G. First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN) combination in advanced breast cancer. Anticancer Res. 2005 Nov-Dec;25(6C):4493-8. PubMed PMID: 16334132.

50: Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Onkologie. 2005 Nov;28(11):558-64. PubMed PMID: 16249641.

51: Matveev BP, Bukharkin BV, Kalinin SA. [Chemotherapy of hormone-resistent cancer of the prostate]. Urologiia. 2005 Jul-Aug;(4):20-3. Russian. PubMed PMID: 16158740.

52: Perry WL 3rd, Shepard RL, Sampath J, Yaden B, Chin WW, Iversen PW, Jin S, Lesoon A, O'Brien KA, Peek VL, Rolfe M, Shyjan A, Tighe M, Williamson M, Krishnan V, Moore RE, Dantzig AH. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. PubMed PMID: 16061639.

53: Dranitsaris G, Evans WK, Milliken D, Zanke B. The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer. J Eval Clin Pract. 2005 Aug;11(4):350-6. PubMed PMID: 16011647.

54: Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. Chemotherapy for non-small cell lung cancer in elderly patients. Chest. 2005 Jul;128(1):132-9. PubMed PMID: 16002926.

55: Andres R, Mayordomo JI, Lara R, Lastra R, Ortega E, Polo E, Lambea J, Isla D, Saenz-Cusi A, Escudero P, Tres A. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer. 2005 Jun;6(2):158-62. PubMed PMID: 16001994.

56: Liu ZJ, Lee WJ, Zhu BT. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause. Cancer Res. 2005 Jul 1;65(13):5802-11. PubMed PMID: 15994956.

57: Fumoleau P, Seidman AD, Trudeau ME, Chevallier B, Ten Bokkel Huinink WW. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs. 1997 Dec;6(12):1853-65. PubMed PMID: 15989586.

58: Furonaka M, Miyazaki M, Nakajima M, Hirata S, Fujitaka K, Kondo K, Yokoyama A, Maeda H, Kohno N. Neutropenic enterocolitis in lung cancer: a report of two cases and a review of the literature. Intern Med. 2005 May;44(5):467-70. Review. PubMed PMID: 15942096.

59: Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther. 2005 Mar;4(3):399-412. PubMed PMID: 15767549.

60: Chikamori M, Takigawa N, Kiura K, Tabata M, Shibayama T, Segawa Y, Ueoka H, Ohnoshi T, Tanimoto M. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line. Anticancer Res. 2004 Nov-Dec;24(6):3911-6. PubMed PMID: 15736431.

61: Gralla RJ, Thatcher N. Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer. 2004 Dec;46 Suppl 2:S41-7. Review. PubMed PMID: 15698531.

62: Han GZ, Liu ZJ, Shimoi K, Zhu BT. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res. 2005 Jan 15;65(2):387-93. PubMed PMID: 15695378.

63: Hanauske AR, Dittrich C, Otero J. Overview of phase I/II pemetrexed studies. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):18-25. Review. PubMed PMID: 15655932.

64: Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res. 2004 Nov 15;10(22):7662-70. PubMed PMID: 15569999.

65: Scifo C, Cardile V, Russo A, Consoli R, Vancheri C, Capasso F, Vanella A, Renis M. Resveratrol and propolis as necrosis or apoptosis inducers in human prostate carcinoma cells. Oncol Res. 2004;14(9):415-26. PubMed PMID: 15490973.

66: Fumoleau P, Cameron D. Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer. Semin Oncol. 2004 Oct;31(5 Suppl 10):45-50. Review. PubMed PMID: 15490374.

67: Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA. Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs. 2004 Oct;15(9):861-9. PubMed PMID: 15457126.

68: Rosell R, Taron M, Camps C, López-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc). 2003 Oct;39(10):775-86. Review. PubMed PMID: 14668933.

69: Chen YM, Perng RP, Lee CS, Lin WC, Tsai CM, Whang-Peng J. Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy. Am J Clin Oncol. 2003 Dec;26(6):567-70. PubMed PMID: 14663373.

70: Suzuki Y, Tokuda Y, Saito Y, Ohta M, Tajima T. Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol. 2003 Oct;33(10):514-7. PubMed PMID: 14623919.

71: Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, Lin MF. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer. 2003 Nov 10;107(3):478-85. PubMed PMID: 14506750.

72: Krasna L, Netikova I, Chaloupkova A, Taislova E, Zimovjanova M, Vesely P, Danes J, Petruzelka L, Matouskova E. Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens. Anticancer Res. 2003 May-Jun;23(3B):2593-9. PubMed PMID: 12894546.

73: Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15;63(12):3154-61. PubMed PMID: 12810643.

74: Kanzawa F, Akiyama Y, Saijo N, Nishio K. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer. 2003 Jun;40(3):325-32. PubMed PMID: 12781432.

75: Urien S, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Deporte-Fety R. Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer Chemother Pharmacol. 2003 Aug;52(2):99-107. Epub 2003 May 27. PubMed PMID: 12768319.

76: Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents. 2002 Jan;2(1):55-70. Review. PubMed PMID: 12678751.

77: Geffen DB, Man S. New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31. Review. PubMed PMID: 12516906.

78: Prémaud A, Rousseau A, Gicquel M, Ragot S, Manceau J, Laurentie M, Marquet P. An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. Toxicol Appl Pharmacol. 2002 Sep 15;183(3):189-97. PubMed PMID: 12383710.

79: Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs. 2002;62(14):2089-126. Review. PubMed PMID: 12269857.

80: Tiburi M, Reguly ML, Schwartsmann G, Cunha KS, Lehmann M, Rodrigues de Andrade HH. Comparative genotoxic effect of vincristine, vinblastine, and vinorelbine in somatic cells of Drosophila melanogaster. Mutat Res. 2002 Aug 26;519(1-2):141-9. PubMed PMID: 12160899.

81: Rogers P, Boxall FE, Allott CP, Stephens TC, Kelland LR. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Eur J Cancer. 2002 Aug;38(12):1653-60. PubMed PMID: 12142057.

82: Hida T, Kozaki K, Ito H, Miyaishi O, Tatematsu Y, Suzuki T, Matsuo K, Sugiura T, Ogawa M, Takahashi T, Takahashi T. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res. 2002 Jul;8(7):2443-7. PubMed PMID: 12114451.

83: Barret JM, Kruczynski A, Etiévant C, Hill BT. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol. 2002 Jun;49(6):479-86. Epub 2002 Apr 6. PubMed PMID: 12107553.

84: Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K. Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull. 2002 Jun;25(6):771-8. PubMed PMID: 12081145.

85: Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Kollmannsberger C, Beyer J, Jonas U, Kanz L. Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol. 1998;16(2):155-62. Review. PubMed PMID: 12073232.

86: Gauvin A, Bressolle F, Martineau P, Astre C, Pinguet F. In vitro schedule-dependent interaction between irinotecan and vinorelbine in NCI H460 non-small cell lung cancer cell line. Anticancer Res. 2002 Mar-Apr;22(2A):905-12. PubMed PMID: 12014670.

87: Georgoulias V. Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Curr Med Chem. 2002 Apr;9(8):869-77. PubMed PMID: 11966449.

88: Li XM, Vincenti M, Lévi F. Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol Int. 2002 Jan;19(1):43-55. PubMed PMID: 11962685.

89: Sun Y. Clinical trials of new anticancer agents in recent years in China. Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:86-7. PubMed PMID: 11890120.

90: Shiraki N, Okamura K, Tokunaga J, Ohmura T, Yasuda K, Kawaguchi T, Hamada A, Nakano M. Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells. Jpn J Cancer Res. 2002 Feb;93(2):209-15. PubMed PMID: 11856485.

91: Girling DJ, Muers MF, Qian W, Lobban D. Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. Semin Oncol. 2002 Feb;29(1):97-101. Review. PubMed PMID: 11836674.

92: Mori T, Ohnishi M, Komiyama M, Tsutsui A, Yabushita H, Okada H. Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test. Oncol Rep. 2002 Mar-Apr;9(2):301-5. PubMed PMID: 11836596.

93: Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol. 2001 Nov;40(2):159-73. Review. PubMed PMID: 11682323.

94: Goldwasser F, Misset JL. [Clinical use of oxaliplatin in solid tumors]. Bull Cancer. 2001 Aug;88 Spec No:S40-4. Review. French. PubMed PMID: 11567913.

95: Inoue A, Saijo N. Recent advances in the chemotherapy of non-small cell lung cancer. Jpn J Clin Oncol. 2001 Jul;31(7):299-304. Review. PubMed PMID: 11518741.

96: Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Malivet V, Chacun C, Jan M, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman J, Pierré A. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Clin Cancer Res. 2001 Aug;7(8):2573-80. PubMed PMID: 11489841.

97: Kreis W, Budman DR, Calabro A. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemother Pharmacol. 2001;47(1):78-82. PubMed PMID: 11221966.

98: Gonçalves A, Braguer D, Carles G, André N, Prevôt C, Briand C. Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol. 2000 Dec 1;60(11):1579-84. PubMed PMID: 11077039.

99: Kobayashi K, Kobayashi T. [Outpatient clinic in Saitama Cancer Center]. Gan To Kagaku Ryoho. 2000 Oct;27(11):1656-61. Review. Japanese. PubMed PMID: 11057315.

100: Trimble EL. Innovative therapies for advanced ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):24-30. Review. PubMed PMID: 10952123.

101: Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos. 2000 Sep;28(9):1121-7. PubMed PMID: 10950859.

102: Gauvin A, Pinguet F, Culine S, Astre C, Gomeni R, Bressolle F. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res. 2000 Jul;6(7):2690-5. PubMed PMID: 10914711.

103: Barret JM, Etiévant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol. 2000;45(6):471-6. PubMed PMID: 10854134.

104: Bengtson EM, Rigas JR. New oral chemotherapeutic agents for lung cancer. Drugs. 1999;58 Suppl 3:57-69. Review. PubMed PMID: 10711843.

105: Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res. 2000 Jan;6(1):297-304. PubMed PMID: 10656461.

106: Kano Y, Akutsu M, Suzuki K, Ando J, Tsunoda S. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res Treat. 1999 Jul;56(1):79-90. PubMed PMID: 10517345.

107: Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999;44(5):355-61. Review. PubMed PMID: 10501907.

108: Hortobagyi GN, Hung MC, Buzdar AU. Recent developments in breast cancer therapy. Semin Oncol. 1999 Aug;26(4 Suppl 12):11-20. Review. PubMed PMID: 10482190.

109: Botta M, Arboscello E, Lerza R, Mencoboni M, Bogliolo G, Pannacciulli I. Effects of docetaxel on the in vitro growth of human myeloid progenitors. Anticancer Res. 1999 May-Jun;19(3A):1855-8. PubMed PMID: 10470127.

110: Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol. 1999;44(4):312-8. PubMed PMID: 10447579.

111: Miller V. Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer. Semin Oncol. 1999 Jun;26(3 Suppl 10):12-4. PubMed PMID: 10437745.

112: Pannacciulli I, Ballarino P, Castello G, Arboscello E, Botta M, Tredici S, Lerza R. In vitro toxicity of taxol based anticancer drug combinations on human hemopoietic progenitors. Anticancer Res. 1999 Jan-Feb;19(1A):409-12. PubMed PMID: 10226575.

113: Culine S, Roch I, Pinguet F, Romieu G, Bressolle F. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int J Oncol. 1999 May;14(5):999-1006. PubMed PMID: 10200354.

114: Shi Q, Chen K, Morris-Natschke SL, Lee KH. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des. 1998 Jun;4(3):219-48. Review. PubMed PMID: 10197041.

115: Weiss AJ, Sabol J, Lackman RD. Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: an effective method of increasing dose intensity. Am J Clin Oncol. 1999 Feb;22(1):38-41. PubMed PMID: 10025378.

116: Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. [Clinical activity spectrum of irinotecan]. Bull Cancer. 1998 Dec;Spec No:21-5. Review. French. PubMed PMID: 9932080.

117: Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer. 1998 Jul;34(8):1250-9. PubMed PMID: 9849488.

118: Lichtman SM. Recent developments in the pharmacology of anticancer drugs in the elderly. Curr Opin Oncol. 1998 Nov;10(6):572-9. Review. PubMed PMID: 9818238.

119: van Hille B, Hill BT. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer Chemother Pharmacol. 1998;42(5):345-56. PubMed PMID: 9771947.

120: Pereira E, Tarasiuk J, Garnier-Suillerot A. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids. Chem Biol Interact. 1998 Jul 3;114(1-2):61-76. PubMed PMID: 9744556.

121: Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997 Sep;54(3):447-72. Review. PubMed PMID: 9279506.

122: Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-19-S13-26. Review. PubMed PMID: 9335513.

123: Pezzuto JM. Plant-derived anticancer agents. Biochem Pharmacol. 1997 Jan 24;53(2):121-33. Review. PubMed PMID: 9037244.

124: Mogi H, Hasegawa Y, Watanabe A, Nomura F, Saka H, Shimokata K. Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro. Cancer Chemother Pharmacol. 1997;39(3):199-204. PubMed PMID: 8996520.

125: Fridborg H, Nygren P, Dhar S, Csoka K, Kristensen J, Larsson R. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells. J Exp Ther Oncol. 1996 Sep;1(5):286-95. PubMed PMID: 9414416.

126: Mouchard-Delmas C, Devie-Hubert I, Dufer J. Effects of the anticancer agent vinorelbine on endothelial cell permeability and tissue-factor production in man. J Pharm Pharmacol. 1996 Sep;48(9):951-4. PubMed PMID: 8910860.

127: Levêque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet. 1996 Sep;31(3):184-97. Review. Erratum in: Clin Pharmacokinet 1997 Apr;32(4):323. PubMed PMID: 8877249.

128: Pauwels O, Gozy M, Van Houtte P, Pasteels JL, Atassi G, Kiss R. Cross resistance and collateral sensitivity between cytotoxic drugs and radiation in two human bladder cell lines. Radiother Oncol. 1996 Apr;39(1):81-6. PubMed PMID: 8735497.

129: Djuanda I, Depenbrock H, Peter R, Block T, Pohlmann G, Rastetter J, Hanauske AR. Efficacy of 5'-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro. Invest New Drugs. 1996;14(2):153-9. PubMed PMID: 8913836.

130: Saijo N, Nishio K, Ohta S, Arioka H, Funayama Y, Fukuoka K, Kurokawa H, Nomoto T, Ishida T, Yamamoto N, Tamura T, Shinkai T, Eguchi K, Ohe Y, Kunito H, Ohtsu T, Sasaki Y. Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Cancer Chemother Pharmacol. 1996;38 Suppl:S11-5. Review. PubMed PMID: 8765409.

131: Prescott LM. Highlights of the Eighth European Cancer Conference. J Int Assoc Physicians AIDS Care. 1995 Dec;1(11):34-5. PubMed PMID: 11363091.

132: Pauwels O, Kiss R, Pasteels JL, Atassi G. Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents. J Pharm Pharmacol. 1995 Oct;47(10):870-5. PubMed PMID: 8583358.

133: Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct;13(10):2567-74. PubMed PMID: 7595708.

134: Knick VC, Eberwein DJ, Miller CG. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst. 1995 Jul 19;87(14):1072-7. PubMed PMID: 7616599.

135: Giaccone G. New drugs in non-small cell lung cancer. An overview. Lung Cancer. 1995 Apr;12 Suppl 1:S155-62. Review. PubMed PMID: 7551924.

136: Masuda N. [Phase III trial of new anticancer agents from a medical oncologists viewpoint]. Gan To Kagaku Ryoho. 1995 Feb;22(3):313-8. Review. Japanese. PubMed PMID: 7880100.

137: Ariyoshi Y, Sugiura T. [New promising anticancer drugs for lung cancer]. Gan To Kagaku Ryoho. 1994 Nov;21(15):2578-84. Review. Japanese. PubMed PMID: 7979416.

138: Burris HA 3rd, Fields S. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol. 1994 Oct;21(5 Suppl 10):14-9; discussion 19-20. Review. PubMed PMID: 7973764.

139: Weiss GR, Burris HA 3rd, Eckardt JR, Fields S, O'Rourke T, Rodriguez GI, Rothenberg ML. New anticancer agents. Cancer Chemother Biol Response Modif. 1994;15:130-51. Review. PubMed PMID: 7779583.

140: Kobayashi S, Sakai T, Dalrymple PD, Wood SG, Chasseaud LF. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneimittelforschung. 1993 Dec;43(12):1367-77. PubMed PMID: 8141830.

141: Tsukagoshi S. [Recent development of new anticancer drugs in Japan]. Nippon Rinsho. 1993 Jul;51(7):1923-9. Review. Japanese. PubMed PMID: 8103565.

142: Le Guellec C, Lacarelle B, Catalin J, Durand A. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5. PubMed PMID: 8258200.

143: Niitani H, Hisakatsu S. [Antimicrotubule agents]. Gan To Kagaku Ryoho. 1993 Jan;20(1):34-41. Review. Japanese. PubMed PMID: 8093658.

144: Budman DR. New vinca alkaloids and related compounds. Semin Oncol. 1992 Dec;19(6):639-45. Review. PubMed PMID: 1462165.

145: Levêque D, Jehl F, Quoix E, Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol. 1992 Dec;32(12):1096-8. PubMed PMID: 1336784.

146: Kawahara M, Furuse K. [Recent results of anticancer drugs acting on microtubules--navelbine, taxol and taxotere for the treatment of lung cancer]. Gan To Kagaku Ryoho. 1992 Nov;19(13):2150-6. Review. Japanese. PubMed PMID: 1359840.

147: Guéritte-Voegelein F, Guénard D, Potier P. [Anticancer substances of vegetable origin. Spindle poisons: vincaleukoblastine, leurocristine and navelbine; taxol and taxotere]. C R Seances Soc Biol Fil. 1992;186(5):433-40. French. PubMed PMID: 1363958.

148: Sahnoun Z, Zhou XJ, Bore P, Monjanel S, Favre R, Durand A, Rahmani R. [Clinical pharmacokinetics of navelbine after oral administration, in vitro metabolism and interindividual variability]. Bull Cancer. 1990;77(11):1115-21. French. PubMed PMID: 2275987.

149: Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP, Meininger V. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol. 1989 Apr;16(2 Suppl 4):9-14. PubMed PMID: 2496470.

150: Boré P, Rahmani R, van Cantfort J, Focan C, Cano JP. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol. 1989;23(4):247-51. PubMed PMID: 2924381.